Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BUB1 | O43683 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.38 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068302 | 0.88 | BUB1 (0.47) | BUB1KCNH2ADORA3PDE5AGUCY1A1 | |
| Etriciguat SCHEMBL29388720 | 0.86 | ADORA3 (0.56) | BUB1KCNH2ADORA3PDE5AGUCY1A1 | |
| Etriciguat SCHEMBL419874 | 0.86 | ADORA3 (0.56) | BUB1KCNH2ADORA3PDE5AGUCY1A1 | |
| SCHEMBL6068406 | 0.85 | BUB1 (0.48) | BUB1KCNH2ADORA3PDE5AGUCY1A1 | |
| SCHEMBL6068522 | 0.83 | ADORA3 (0.49) | BUB1KCNH2ADORA3PDE5AGUCY1A1 | |
| SCHEMBL18212218 | 0.82 | ADORA3 (0.58) | KCNH2ADORA3PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL2509702 | 0.81 | GUCY1A1 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL2508154 | 0.81 | GUCY1A1 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL25688767 | 0.75 | PDE5A (0.57) | BUB1KCNH2ADORA3PDE5A | |
| SCHEMBL25791771 | 0.74 | ADORA3 (0.34) | BUB1KCNH2ADORA3PDE5AGUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135474-B2 | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER HEALTHCARE AG (DE) | 2006-11-14 | — | — | US | disclosed |
| EP-1509228-B1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | BAYER HEALTHCARE AG (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1509228-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | Bayer HealthCare AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| EP-1509228-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | Bayer HealthCare AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097063-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097063-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | PDE3B, PDE5A, PDE3A | L3MBTL1 2809/4885BUB1 2595/4885KCNH2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.